Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications

Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated i...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2002-03, Vol.86 (6), p.979-982
Main Authors: Sigalotti, L, Coral, S, Altomonte, M, Natali, L, Gaudino, G, Cacciotti, P, Libener, R, Colizzi, F, Vianale, G, Martini, F, Tognon, M, Jungbluth, A, Cebon, J, Maraskovsky, E, Mutti, L, Maio, M
Format: Article
Language:English
Subjects:
Animals
Antigens
Antigens, Neoplasm - analysis
Antineoplastic agents
Azacitidine - pharmacology
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
DNA Methylation
Drug Resistance
Epidemiology
Experimental Therapeutics
Female
Humans
Immunotherapy
Male
Medical research
Medical sciences
Melanoma
Melanoma-Specific Antigens
Membrane Proteins
Mesothelioma
Mesothelioma - immunology
Mesothelioma - therapy
Molecular Medicine
Neoplasm Proteins - analysis
Oncology
Pharmacology. Drug treatments
Pleural effusion
Proteins - analysis
Rabbits
Repressor Proteins - analysis
Testis - immunology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6600174